View in EDS HTML Full Text PDF Full Text

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease.

Saved in:
Bibliographic Details
Title: Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease.
Authors: Heitmann JS; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany., Schlenk RF; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany.; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Dörfel D; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Department of Hematology, Oncology and Immunology, KRH Klinikum Siloah, Hannover, Germany., Kayser S; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany.; Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany.; Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg-Hessen, Mannheim, Germany., Döhner K; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Heuser M; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Thol F; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Kapp-Schwoerer S; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Labrenz J; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany., Edelmann D; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany.; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Märklin M; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany., Vogel W; Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany., Bethge W; Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany., Walz JS; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.; Department of Peptide-Based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany., Große-Hovest L; Synimmune GmbH, Tübingen, Germany., Steiner M; Synimmune GmbH, Tübingen, Germany., Jung G; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany., Salih HR; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, University of Tübingen, Tübingen, Germany. helmut.salih@med.uni-tuebingen.de.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany. helmut.salih@med.uni-tuebingen.de.
Source: Journal of hematology & oncology [J Hematol Oncol] 2023 Aug 17; Vol. 16 (1), pp. 96. Date of Electronic Publication: 2023 Aug 17.
Publication Type: Multicenter Study; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37587502
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Heitmann+JS%22">Heitmann JS</searchLink>; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Schlenk+RF%22">Schlenk RF</searchLink>; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany.; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Dörfel+D%22">Dörfel D</searchLink>; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Department of Hematology, Oncology and Immunology, KRH Klinikum Siloah, Hannover, Germany.<br /><searchLink fieldCode="AU" term="%22Kayser+S%22">Kayser S</searchLink>; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany.; Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany.; Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg-Hessen, Mannheim, Germany.<br /><searchLink fieldCode="AU" term="%22Döhner+K%22">Döhner K</searchLink>; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Heuser+M%22">Heuser M</searchLink>; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.<br /><searchLink fieldCode="AU" term="%22Thol+F%22">Thol F</searchLink>; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.<br /><searchLink fieldCode="AU" term="%22Kapp-Schwoerer+S%22">Kapp-Schwoerer S</searchLink>; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Labrenz+J%22">Labrenz J</searchLink>; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Edelmann+D%22">Edelmann D</searchLink>; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany.; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Märklin+M%22">Märklin M</searchLink>; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Vogel+W%22">Vogel W</searchLink>; Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Bethge+W%22">Bethge W</searchLink>; Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Walz+JS%22">Walz JS</searchLink>; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.; Department of Peptide-Based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Große-Hovest+L%22">Große-Hovest L</searchLink>; Synimmune GmbH, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Steiner+M%22">Steiner M</searchLink>; Synimmune GmbH, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Jung+G%22">Jung G</searchLink>; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Salih+HR%22">Salih HR</searchLink>; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, University of Tübingen, Tübingen, Germany. helmut.salih@med.uni-tuebingen.de.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany. helmut.salih@med.uni-tuebingen.de.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101468937%22">Journal of hematology & oncology</searchLink> [J Hematol Oncol] 2023 Aug 17; Vol. 16 (1), pp. 96. <i>Date of Electronic Publication: </i>2023 Aug 17.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Multicenter Study; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Biomed+Central%22">Biomed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101468937 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1756-8722 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217568722%22">17568722 </searchLink><i>NLM ISO Abbreviation: </i>J Hematol Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37587502
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s13045-023-01490-w
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 96
    Titles:
      – TitleFull: Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Heitmann JS
      – PersonEntity:
          Name:
            NameFull: Schlenk RF
      – PersonEntity:
          Name:
            NameFull: Dörfel D
      – PersonEntity:
          Name:
            NameFull: Kayser S
      – PersonEntity:
          Name:
            NameFull: Döhner K
      – PersonEntity:
          Name:
            NameFull: Heuser M
      – PersonEntity:
          Name:
            NameFull: Thol F
      – PersonEntity:
          Name:
            NameFull: Kapp-Schwoerer S
      – PersonEntity:
          Name:
            NameFull: Labrenz J
      – PersonEntity:
          Name:
            NameFull: Edelmann D
      – PersonEntity:
          Name:
            NameFull: Märklin M
      – PersonEntity:
          Name:
            NameFull: Vogel W
      – PersonEntity:
          Name:
            NameFull: Bethge W
      – PersonEntity:
          Name:
            NameFull: Walz JS
      – PersonEntity:
          Name:
            NameFull: Große-Hovest L
      – PersonEntity:
          Name:
            NameFull: Steiner M
      – PersonEntity:
          Name:
            NameFull: Jung G
      – PersonEntity:
          Name:
            NameFull: Salih HR
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 17
              M: 08
              Text: 2023 Aug 17
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1756-8722
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Journal of hematology & oncology
              Type: main
ResultId 1